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SUMMARY

The diversity and complexity of the cancer transcriptome may contain transcripts unique to the tumor
environment. Here, we report a LIN28B variant,
LIN28B-TST, which is specifically expressed in hepatocellular carcinoma (HCC) and many other cancer
types. Expression of LIN28B-TST is associated
with significantly poor prognosis in HCC patients.
LIN28B-TST initiates from a de novo alternative transcription initiation site that harbors a strong promoter regulated by NFYA but not c-Myc. Demethylation of the LIN28B-TST promoter might be a
prerequisite for its transcription and transcriptional
regulation. LIN28B-TST encodes a protein isoform
with additional N-terminal amino acids and is critical
for cancer cell proliferation and tumorigenesis. Our
findings reveal a mechanism of LIN28B activation in
cancer and the potential utility of LIN28B-TST for
clinical purposes.
INTRODUCTION
The application of deep sequencing for RNA analysis has allowed for an unprecedented view of the human transcriptome,
revealing the diversity and complexity in transcript identity and
splicing (Barash et al., 2010; Djebali et al., 2012; Mercer et al.,
2011). Cancer is a heterogeneous and complex disease
involving genetic and epigenetic alterations that result in a
more complicated transcriptome. Hence, there is tremendous
potential to yield tumor-specific transcripts (TSTs) in the cancer
transcriptome. The detection and characterization of TSTs such
as fusion transcripts are of great importance for clinical purposes
and for understanding carcinogenesis (Mertens et al., 2015; Mitelman et al., 2007). Fusion transcripts derived from DNA translocation are a typical type of TST but have only been validated in
some cancers. Dysregulation of transcription splicing and epigenetic alteration may result in abundant TSTs, including specific
mRNA variants and intergenic transcripts. However, the identification and functional roles of these specific transcripts in cancer
remain largely unknown.

The LIN28 family, including LIN28A and LIN28B, is highly expressed during embryogenesis but silent in most adult tissues
(Shyh-Chang and Daley, 2013). LIN28 can block the maturation
of the tumor suppressor microRNA let-7 family and mediate
diverse biological functions (Shyh-Chang and Daley, 2013; Viswanathan et al., 2008). LIN28A, in combination with NANOG,
OCT4, and SOX2, can reprogram human somatic cells to pluripotent stem cells (Yu et al., 2007). LIN28A also regulates mammalian stem cell self-renewal and promotes tissue repair (Kim et al.,
2014; Shyh-Chang et al., 2013). LIN28B is highly expressed in
various types of human cancer (Helland et al., 2011; King et al.,
2011a, 2011b; Viswanathan et al., 2009; Yang et al., 2010).
Mice overexpressing LIN28B develop multiple tumors, including
lymphoma (Beachy et al., 2012), neuroblastoma (Molenaar et al.,
2012), colonic adenocarcinoma (Madison et al., 2013), Wilms tumor (Urbach et al., 2014), hepatoblastoma, and hepatocellular
carcinoma (Nguyen et al., 2014). These mouse models suggest
that LIN28B alone is sufficient to drive cancer. In addition to tumor initiation, LIN28B is necessary for maintenance of liver cancer (Nguyen et al., 2014). However, the mechanism of LIN28B
activation in cancer remains unclear.
Here, we investigated the potential TSTs in the cancer
transcriptome and found an LIN28B variant that is specifically
expressed in hepatocellular carcinoma (HCC) and many other
tumor types. We showed that LIN28B-TST is produced from a
de novo alternative transcription initiation site, which harbors a
strong promoter. LIN28B-TST encodes a long protein isoform
with additional N-terminal amino acids and is critical for cancer
cell proliferation and tumorigenesis.
RESULTS
RNA-Seq Analyses Reveal a LIN28B Tumor-Specific
Variant in Multiple Cancers
We first performed transcriptome analyses of different normal
and cancerous tissues, as well as several cell lines, by RNA
sequencing (RNA-seq) and investigated the existence of potential TSTs (Figure S1A). We detected a substantial number of
TSTs, including 430 intergenic transcripts and 1,385 variants
overlapping with annotated genes (Figure 1A; Table S1). Of these
TSTs, we noted an LIN28B variant showing a high expression
level and percentage splicing index, named LIN28B-TST
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Figure 1. RNA-Seq Analyses Revealed a LIN28B Tumor-Specific Transcript, LIN28B-TST, in Multiple Cancers
(A) Dot plot of TST expression levels with respect to corresponding percentage splicing index (PSI) in cancer samples.
(B) Distribution of RNA-seq reads for the LIN28B gene locus in various RNA-seq libraries.
(C) Expression levels of LIN28B-TST and LIN28B-WT in different cancers from TCGA cohort (Table S2).
(D) Expression levels of LIN28B-TST and LIN28B-WT in fetal liver, normal liver, hepatoblastoma, and HCC. Medians are indicated within samples expressing
LIN28N-TST or LIN28B-WT.
(E) Overall survival of HCC patients with (+, n = 35) or without (, n = 22) LIN28B-TST expression. The p values were calculated using the log-rank test.
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Figure 2. LIN28B-TST Is Produced by Alternative Transcription Initiation with a Strong Promoter Independent of c-Myc

(A) ChIP-seq and 50 RACE profiles of LIN28B-TST at the alternative transcription initiation site in HuH-7 cells.
(B) Luciferase reporter assay of LIN28B-TST promoter with serial deletions from the 50 end in HEK293T cells.
(C) Relative activity of the LIN28B-TST promoter in various cell lines. Data were presented as means ± SEM and representative of three independent experiments.

(legend continued on next page)
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(Figure 1A). We found that LIN28B-TST was expressed in HCC
tissue, HuH-7 HCC cells, and NCI-H1299 lung cancer cells, while
wild-type LIN28B (LIN28B-WT) was expressed in HEK293T cells
(Figure 1B). Neither variant was expressed in normal liver tissue
(Figure 1B). The LIN28B transcript contains two new exons at the
50 end and three exons identical to LIN28B-WT exons 2–4 (Figure 1B). We confirmed the presence of the LIN28B-TST transcript by Northern blotting and rapid amplification of cDNA
ends (RACE) analysis (Figures S1C–S1F). LIN28B-TST differs
from another alternative transcript of LIN28B, which was previously identified in medulloblastoma (Hovestadt et al., 2014)
and expressed in H1 embryo stem cells (Figure S2A). Additionally, we found that the promoter region and new exons of
LIN28B-TST are only conserved in primates, but not in other
mammals (Figure S2B), suggesting that LIN28B-TST is a primate-specific variant.
To evaluate LIN28B-TST expression, we screened more than
7,000 tumors from 22 different cancer types in The Cancer
Genome Atlas (TCGA) RNA-seq datasets. LIN28B was expressed in 10.2% of all cancers (Table S2). Of the LIN28Bexpressing tumors, LIN28B-TST was specifically expressed in
HCC (91.5%, 54/59) and many other cancer types, such as cervical and endocervical cancer (CESC; 86.2%, 25/29), brain lower
grade glioma (LGG; 85.2%, 23/27), breast invasive carcinoma
(BRCA; 69.8%, 30/43), skin cutaneous melanoma (SKCM;
68.1%, 32/47), and lung squamous cell carcinoma (LUSC;
50%, 59/118) (Figure 1C; Table S2). To distinguish and quantify
the expression of LIN28B-WT and LIN28B-TST, we designed
specific primer sets and performed qRT-PCR in a variety of cells
(Figure S2C). Notably, qRT-PCR assay was more sensitive
than RNA-seq analyses. We observed that LIN28B-TST was
frequently expressed in HCC tissues (38.2%, 49/128) but not
in normal or fetal liver tissues (Figure 1D). In contrast, the
LIN28B-WT was detected in fetal liver tissue and sporadically
expressed in HCC tissues (Figure 1D). Kaplan-Meier survival
analysis showed that HCC patients with LIN28B-TST expression
had poorer outcomes (Figure 1E). We also detected LIN28B
expression in pediatric hepatoblastoma (HB) and found predominant LIN28B-WT expression in hepatoblastoma tissues but no
LIN28B-TST expression (Figure 1D). Further analyses of Encyclopedia of DNA Elements (ENCODE) normal-tissue RNA-seq
data showed that LIN28B-TST is only expressed at low levels
in partial testis tissues and that LIN28B-WT is expressed in brain
and testis tissues. Considering the immune-privileged status
of the testis, LIN28B-TST might be regarded as a bona fide
tumor-specific transcript.
LIN28B-TST Is Produced by Alternative Transcription
Initiation with a Strong Promoter
The RNA-seq profile of the LIN28B variant suggested an
alternative transcription initiation (ATI) site approximately 20 kb
upstream of LIN28B-WT (Figure 1B). We performed 50 RACE

and mapped the ATI site to a region on chromosome 6
at chr6:104,937,026 (hg38). Chromatin immunoprecipitation
sequencing (ChIP-seq) and ChIP-qPCR revealed significant
enrichment of histone H3K4me3, H3K27Ac, and RNA polymerase II (Pol II) near the ATI site (Figures 2A and S3A). These data
indicated that LIN28B-TST originates from a newly established
ATI site that is associated with characteristic chromatin alterations. To evaluate whether the region at the ATI site could function as a promoter, we cloned the putative LIN28B-TST promoter
fragment into a luciferase reporter. The luciferase reporter assay
showed that the activity of the LIN28B-TST promoter was over
20-fold higher than LIN28B-WT or the Simian vacuolating virus
40 (SV40) promoter in HEK293T cells (Figure 2B). A series of constructs with different deletions revealed a 200-bp core promoter proximal to the ATI site (Figure 2B). Strikingly, all cells
showed strong promoter activity, including the LIN28B-TSTexpressing cells, LIN28B-WT-expressing cells, and LIN28B
null-expressing cells (Figure 2C), suggesting that transcription
of LIN28B-TST is restricted by epigenetic mechanisms. We
also investigated whether LIN28B-TST could be modulated by
the c-Myc oncogene, which was found to directly regulate the
expression of LIN28B-WT (Chang et al., 2009). Inhibition of
c-Myc by small interference RNA (siRNA) or Bromodomain and
extra terminal protein (BET) inhibitor JQ1 remarkably decreased
the expression of c-Myc and LIN28B in LIN28B-WT-expressing
HepG2 cells, while LIN28B-TST expression was not altered after
silencing of c-Myc expression in LIN28B-TST-expressing HuH-7
cells (Figure 2E). ChIP qPCR showed that c-Myc could bind to
the promoter of LIN28B-WT but not LIN28B-TST (Figure S3B),
suggesting that the regulation of LIN28B-TST is independent
of c-Myc expression. Considering that BET inhibitor JQ1 represents a promising therapeutic agent for a broad spectrum of
caners and c-Myc is the key target gene, we wondered whether
expression of LIN28B-TST is resistant to its treatment. We noted
that the half maximal inhibitory concentration (IC50) value of JQ1
in LIN28B-TST-expressing HuH-7 cells (IC50 = 30.1 nM) was
much higher than that in LIN28B-WT-expressing HepG2 cells
(IC50 = 5.08 nM) (Figures S3C and S3D). Importantly, the IC50
value of JQ1 was significantly decreased in LIN28B-TSTsilencing HuH-7 cells (IC50 = 3.91 nM), almost 13% of the value
in the control cells (Figure S3C). Furthermore, ectopic expression of LIN28B-TST led to the increase of the IC50 value in
HepG2 cells (IC50 = 33.3 nM), compared to the control cells
(Figure S3D). These findings suggested that expression of
LIN28B-TST contributes to BET inhibitor JQ1 resistance and
that inhibition of LIN28B-TST might be a potential strategy to
sensitize LIN28B-TST-expressing cancers to JQ1.
To explore the transcription factors (TFs) that regulate the
LIN28B-TST, we first scanned the LIN28B-TST promoter sequences, using PROMO and TFBIND, and found a panel of 28
TFs that possess putative binding sites in the LIN28B-TST promoter region. We then performed a siRNA knockdown screening

(D) Immunoblots of LIN28B and c-Myc expression in cells treated with 1 mM JQ1 or transfected siRNA targeting c-Myc for 2 days. b-actin (ACTB) was used as the
loading control.
(E) NFYA enrichment near the ATI site of LIN28B-TST was assessed by ChIP qPCR in HuH-7 cells.
(F) Activities of LIN28B-TST promoter reporters with different lengths were determined in HuH-7 cells transfected with siRNAs targeting NFYA.
(G) Immunoblots of LIN28B and NFYA expression in cells transfected with siRNA targeting NFYA for 2 days. b-actin (ACTB) was used as loading control.
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Figure 3. Demethylation of the LIN28B-TST Promoter Is Associated with Its Expression
(A) Schematic diagram showing the position of 2 CpG islands at the promoter region of LIN28B-TST. Promoter methylation status was analyzed by bisulfite
sequencing. Filled circles denote methylated cytosines, and open circles denote unmethylated cytosines at the indicated CpG sites.
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to evaluate their effect on LIN28B-TST expression in HuH-7
cells. Of note, three TFs (NFYA, YY1, and TFAP4) were identified
to regulate LIN28B-TST expression (Figure S3E), and NFYA had
the most significant effect. NFYA is a pioneer transcription factor
during spermatogonial stem cell development and preimplantation development (Guo et al., 2017; Lu et al., 2016). A binding site
of NFYA (CCAAT) is present in the LIN28B-TST promoter (Figure S3F). ChIP qPCR, luciferase reporter, and western blot assays confirmed that NFYA could directly regulate the expression
of LIN28B-TST but not LIN28B-WT (Figures 2F–2H).
Demethylation of the LIN28B-TST Promoter Is
Associated with Its Expression
To evaluate whether CpG methylation of the LIN28B-TST promoter is associated with its expression, we performed bisulfite
sequencing in regions flanking the ATI site. Two CpG islands
were found in the LIN28B-TST promoter regions (Figure 3A).
Compared to LIN28B-TST null-expressing samples, the
LIN28B-TST-expressing samples showed lower CpG methylation in the second CpG island (Figure 3A). To test whether demethylation at the CpG site is sufficient to induce its expression,
we investigated the expression of LIN28B-TST in LIN28B null or
LIN28B-WT-expressing cells in the presence of the DNA methyltransferase inhibitor 5-aza-deoxycytidine (5-AZA). Treatment
with 5-AZA strongly activated LIN28B-TST mRNA and protein
expression in LIN28B null-expressing SK-HEP-1 and AGS cells
(Figures 3B and 3C). Moreover, the induction of LIN28B-TST
significantly decreased LIN28B-WT mRNA and protein expression in wild-type LIN28B-expressing HEK293T and A549 cells
(Figures 3D and 3E). We further explored whether the NFYA
regulation of LIN28B-TST depends on its DNA methylation
status. We introduced NFYA expression into LIN28B null or
LIN28B-WT-expressing cells with or without 5-AZA treatment.
We observed that ectopic expression of NFYA alone could not
induce LIN28B-TST expression in these cells (Figures 3F and
3G). Interestingly, in the presence of 5-AZA, NFYA could increase the mRNA and protein levels of LIN28B-TST (Figures 3F
and 3G). These results indicate that demethylation of the
LIN28B-TST promoter might be a prerequisite for its transcription and transcriptional regulation.
LIN28B-TST Encodes a Protein Isoform with Additional
N-Terminal Amino Acids and Is Critical for Cancer Cell
Proliferation and Tumorigenesis
The LIN28B-TST transcript contains two predicted in-frame start
codons (ATGs) at the 50 end, resulting in proteins with additional
N-terminal amino acids (Figure 4A). Immunoblots of different
cancer cell lines expressing LIN28B-TST revealed a predominant band, suggesting that LIN28B-TST is translated mainly
from the first start codon (Figure S2D). We further mutated the
two start codons individually or in combination. Immunoblots revealed that each mutated form of LIN28B-TST no longer pro-

duced the corresponding protein band (Figure 4B). We also
prepared a rabbit antibody against the additional N-terminal
amino acids. Immunoblots showed that this antibody specifically
recognized the primary LIN28B-TST isoform but not the minor
isoform or LIN28B-WT (Figures 4B and S2D). Using this specific
LIN28B-TST antibody, we detected the expression of LIN28-TST
in HCC tissues but not in normal liver tissues by immunoblotting
and immunohistochemistry (Figures 4C and 4D).
Because the LIN28B-TST protein contains all of the
functional domains of LIN28B-WT (Figure 4A), we speculated
that LIN28B-TST would have functions similar to those of
LIN28B-WT. To test this notion, we ectopically expressed
LIN28B-TST or LIN28B-WT in LIN28B null-expressing SK-HEP-1
cells. We found that either LIN28B-TST or LIN28B-WT significantly suppressed the expression of let-7 family members (Figure 4E). Consistently, overexpression of either LIN28B-TST or
LIN28B-WT increased the levels of let-7 target genes, including
HMGA2, and IGF2BP1, -2, and -3. (Figure 4F). We also noted
that the protein level of LIN28B-TST was higher than that of
LIN28B-WT in cells infected with the same amount of lentivirus,
which may be due to the different translation efficiency or protein
stability. By using cycloheximide (CHX), a protein synthesis inhibitor, we observed that the stability of the LIN28B-TST protein level
is much higher than that of LIN28B-WT (Figure S4A). We further
used siRNAs and CRISPR/Cas9 technology to knockdown
LIN28B-TST expression and observed significant inhibition of
cell growth and cell-colony formation (Figures 4G and 4H; Figures
S4B–S4D). Silencing of LIN28B-TST also dramatically inhibited
the tumorigenic ability and reduced the tumor weight and volume
of HuH-7 cells (Figures 4I and 4J). All together, these results indicated that LIN28B-TST is critical for cancer cell proliferation and
tumorigenesis and may serve as a specific target for cancer
treatment.
DISCUSSION
In this study, we provide a mechanism of LIN28B activation
through alternative transcription initiation and epigenetic alteration. Similar to the genesis of ALKATI, a ALK transcript in several
cancer types (Wiesner et al., 2015), LIN28B-TST is also produced from a new transcription initiation site. However, these
two transcripts use distinct transcriptional activation mechanisms. The ALKATI expression is mainly driven by the long terminal repeat (LTR) promoter. Despite the presence of LTR within
the LIN28B-TST promoter region, it is not considered a core
component of the LIN28B-TST promoter. The core promoter of
LIN28B-TST showed ubiquitously strong activity independent
of cell types, and LIN28B-TST expression level correlates with
its promoter methylation status, indicating that epigenetic alterations may contribute to the activation of LIN28B-TST.
Identifying molecules specific to tumor is essential for the deciphering of the cancer development and progression, as well as for

(B–E) SK-Hep1 (B and C), AGS (B and C), HEK-293T (D and E) and HepG2 (D and E). Cells were treated with or without 10 mM 5-AZA for 6 days and then harvested
for qPCR and western blot assays. qPCR data were presented as means ± SEM and representative of three independent experiments.
(F–I) The LIN28B-WT-expressing HEK293T (F and G) or LIN28B null-expressing SK-HEP-1 (H and I) cells were infected with NFYA lentivirus, treated with or
without 10 mM 5-AZA for 6 days, and then harvested for qPCR and western blot assays.
Data are representative of three independent experiments, and qPCR data are presented as means ± SEM. *p < 0.05; **p < 0.01.

Cell Reports 22, 2016–2025, February 20, 2018 2021

B

A
LIN28B-TST

Exon 1
1.ATG

LIN28B-WT

Exon 3

2

Exon 4

LIN28B-TST

Exon 5

2.ATG

Control

TAA

Exon 1

Exon 2

Exon 3

Exon 4

ATG

-

WT

1

2

1+2

ATG->AGG

35 kD

LIN28B

35 kD

LIN28B-TST

TAA

CSD

CCHX x2

LIN28B-TST-primary

55 kD

LIN28B-TST-minor

ACTB
40 kD

LIN28B-WT

D

HCC

Normal liver

HCC patients
HCC1

HuH-7

HEK-293T

C

HCC2

N

T

HCC3

N

T

T

H&E

N

LIN28B-TST

35 kD

ACTB

40 kD

LIN28B-TST
5 μm

G

E

I

si-LIN28B-TST
1
2

Ctrl

Tumor volume (cm3)

1.0
0.6

0.5

***
let-7a

***

let-7d*

***

***

let-7f

******

0.4

***
0.2

1

2
3
Days

4

70 kD
55 kD
70 kD
55 kD

TST

***

10

15

20

25

Days

Ctrl

LIN28B-TST-KD

LIN28B-TST-KD

IGF2BP1
IGF2BP2
0.8
IGF2BP3

HMGA2
15 kD
40 kD

*

J
Ctrl

ACTB

3

Ctrl
LIN28B-TST-KD

0.6
OD 450

55 kD

WT

0.5

5

H
Ctrl

1.0

0.0
0

LIN28B
70 kD

1.5

***

0.0

let-7g

F

Ctrl
si-LIN28B-TST-1
si-LIN28B-TST-2

0.4

***

0.2
0.0

0

1

2

3
Days

4

5

Tumor weight (g)

** **
0.0

Ctrl
LIN28B-TST-KD

2.0

OD 450

Relative expression level

1.5

Ctrl
LIN28B-WT
LIN28B-TST

*

2
1
0
Ctrl

LIN28B-TST-KD

(legend on next page)

2022 Cell Reports 22, 2016–2025, February 20, 2018

cancer diagnosis and therapy. DNA mutations constitute the major focus of tumor-specific discovery efforts to date. The diversity
and complexity of cancer transcriptome hold the potential to yield
TSTs in cancer. We proposed that dysregulation of transcription
splicing and epigenetic alteration may result in abundant TSTs,
such as specific mRNA variants and intergenic transcripts. In
this study, we investigated the existence of these potential TSTs
by RNA-seq and transcriptome analyses. Fusion transcripts
were not included in our bioinformatics pipelines. We detected
a substantial number of TSTs, suggesting widespread TSTs in
cancer. Notably, we only considered the transcripts that have
not been annotated previously. The number of TSTs could be underappreciated. In addition, the TST candidates could be false
positive due to the limited set of samples. The analyses of large
databases of transcriptome sequencing data derived from tumors
and normal tissues such as TCGA and the Genotype-Tissue
Expression (GTEx) project are suggested for future study.
In this study, we showed that the function of LIN28B-TST is
similar to that of LIN28B-WT. However, the detailed mechanism
of how the additional amino acids of LIN28B-TST may contribute
to the extraordinarily high protein stability has not yet been
elucidated. In addition, LIN28B-TST expression is independent
of the c-Myc oncogene, and LIN28B-TST-expressing cells are
resistant to the BRD4 inhibitor JQ1. Moreover, LIN28B-TST
expression is associated with significantly poorer prognosis in
HCC patients. The LIN28B-TST-expressing tumors may represent a subtype in cancer. Such tumors would be more aggressive and resistant to therapy, possibly due to the stem cell
phenotype by LIN28B expression (Shyh-Chang and Daley,
2013). HCC is a leading cause of cancer mortality and is
increasing in incidence worldwide. Chemotherapy for HCC
has been quite ineffective. Our findings suggested that
LIN28B-TST may serve as an ideal and promising target candidate for HCC therapy. For instance, LIN28B-TST may be targeted by epigenetic compounds, siRNA, or antisense oligonucleotide (ASO) without affecting wild-type LIN28B expression.
In addition, the specific additional amino acids may be a neoepitope candidate for tumor immunotherapy.
In conclusion, we identified a tumor-specific LIN28B transcript
variant, LIN28B-TST, in HCC and many other cancers. Unlike
wild-type LIN28B, LIN28B-TST initiates from a de novo alternative transcription initiation site harboring a strong promoter

independent of c-Myc expression. The LIN28B-TST-expressing
tumors may represent a subtype of aggressive cancer. These
findings provide new insight into the diversity and complexity
of LIN28B transcriptional regulation, and THEY suggest a
mechanism of LIN28B activation in cancer and the potential of
LIN28B-TST in cancer diagnosis and therapy.
EXPERIMENTAL PROCEDURES
Detailed materials and methods can be found in the Supplemental Experimental Procedures.
RNA-Seq Analysis
The RNA-seq data for six normal tissues (brain, heart, liver, lung, colon, and
stomach) and seven cancer tissues (hepatocellular carcinoma, colorectal cancer, gastric cancer, kidney clear cell carcinoma, bladder urothelial carcinoma,
breast cancer, and prostate cancer) were previously described (Zheng
et al., 2016). HuH-7, NCI-H1299, and HEK293T cells were also subjected to
RNA-seq. Sequencing reads from RNA-seq data were aligned using the spliced
read aligner HISAT2, v2.0.4 (Kim et al., 2015), which was supplied with the
Ensembl human genome assembly (Genome Reference Consortium GRCh38)
as the reference genome. Specifically, a two-step mapping strategy was used
to combine splice junctions from all samples that could be used to annotate
mapped reads. In the first round of mapping, HISAT2 was provided with known
splice sites extracted from GENCODE annotation, v24 (Harrow et al., 2012), using hisat2_extract_splice_sites.py script. At the end of the first mapping step, all
splice junctions in each sample were combined across samples to obtain a master set of combined junctions. Next, a second round of mapping was performed,
with the master set of junctions generated in the first step supplied using the option ‘‘–novel-splice site-infile.’’ The read alignments were provided as input into
StringTie, v1.2.3 (Pertea et al., 2015), for transcriptome assembly. GENCODE,
v24, was used as the transcript model reference annotation to guide the assembly process. Transcripts were assembled individually for each sample and then
merged to generate a non-redundant set of transcripts observed in all RNA-seq
samples. The Cufflinks program (Trapnell et al., 2012) was used to produce
expression levels for the merged transcriptome in each sample at the gene
and transcript levels in FPKM (fragments per kilobase of transcript per million
mapped reads) units. The percentage splicing index of each transcript—which
denotes the fraction of each transcript’s abundance over its parent gene’s abundance—was calculated. Only high-confidence transcripts containing at least
two exons and >0.1 FPKM were considered. TSTs exclusively expressed in tumor samples were extracted by excluding all annotated transcripts (GENCODE,
v24) and those expressed in normal samples.
Cell Culture and Chemical Reagents
HEK293T, HuH-7, and SK-HEP-1 cells were cultured in DMEM; NCI-H1299
cells were cultured in RPMI-1640 medium (GIBCO); HCT-116 cells were

Figure 4. LIN28B-TST Encodes a Protein Isoform with Additional N-Terminal Amino Acids and Is Critical for Cancer Cell Proliferation and
Tumorigenesis
(A) Schematic illustrations of LIN28B transcript variants and corresponding isoforms. Start codons (ATG) and stop codons (TAA) are indicated by arrows.
(B) Immunoblots of cells with expression of LIN28B-WT and LIN28B-TST. The two predicted start codons of LIN28B-TST were mutated from ATG to AGG,
individually or in combination, as indicated.
(C) Immunoblots of HEK293T cells, HuH-7 cells, and HCC patients with the LIN28B-TST antibody. T, HCC tissue; N, matched non-tumor tissue.
(D) Immunostaining of HCC and normal liver tissues by the LIN28B-TST antibody.
(E) Expression levels of let-7 family microRNAs in SK-HEP-1 cells ectopically expressing LIN28B-WT or LIN28B-TST. Data are presented as means ± SEM and
representative of three independent experiments.
(F) Immunoblots of IGFBP1-3 and HMGA2 in SK-HEP-1 cells ectopically expressing LIN28B-WT or LIN28B-TST.
(G and H) Colony formation assay and cell proliferation assay of HuH-7 cells with or without LIN28B-TST knockdown by siRNAs (G) or CRISPR/Cas9 (H). Two
siRNAs targeting LIN28B-TST, si-LIN28N-TST-1 and si-LIN28B-TST-2, were used. Non-targeting siRNA was used as a negative control (Ctrl). A total of 3 small
guide RNAs (sgRNAs) targeting LIN28B-TST were used, and the detailed results are presented in Figure S3. OD 450, optical density 450.
(I and J) The volume (I) and weight (J) of HuH-7 xenograft tumors with or without LIN28B-TST knockdown. Data are presented as means ± SEM (I) or median (J)
(n = 6 mice per group).
*p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S3.
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cultured in McCoy’s 5A medium (GIBCO); and AGS and A549 cells were
cultured in F-12K medium (GIBCO) supplemented with 10% fetal bovine
serum (GIBCO), 100 IU/mL penicillin-streptomycin (GIBCO) in a 37 C incubator with 5% CO2 and a humidified atmosphere. JQ1 was purchased from
Selleck Chemicals (Houston, TX, USA); CHX, and 5-AZA were purchased
from Sigma-Aldrich (St. Louis, MO, USA).
Antibodies
LIN28B-TSTs were generated by GenScript (Nanjing, China) and raised
against the distinct N-terminal immunogen of LIN28B-TST (HRRQVLQKR
MRSFNQVSSAP).
RNA Extraction, Reverse Transcription, and Real-Time qPCR
Total RNA was extracted from tissues or cells using TRIzol reagent. cDNA was
synthesized using the PrimeScript RT Reagent Kit (TaKaRa, Shiga, Japan).
Real-time qPCR analyses were performed using SYBR Premix Ex TaqII
(TaKaRa). Mature microRNAs were quantified with specific primers and
probes using TaqMan MicroRNA Assays (Applied Biosystems, Foster City,
CA, USA). U6 small nuclear RNA (snRNA) served as a loading control.
Luciferase Assays
Cells were cultured in 24-well plates and co-transfected with 50 ng firefly luciferase reporter plasmid and 10 ng Renilla luciferase reporter (pRL-TK) plasmid.
After 48 hr of incubation, firefly and Renilla luciferase activities were measured
using the Dual-Luciferase Reporter Assay System (Promega).
DNA Methylation Analysis
Genomic DNA was extracted using the AllPrep DNA/RNA Mini Kit (QIAGEN).
Two micrograms of genomic DNA were treated with sodium bisulfite using
the EpiTect system (QIAGEN) following the manufacturer’s protocol.
Western Blotting
Proteins were separated on a 10% or 14% SDS-polyacrylamide gel and transferred on to a nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). The membrane was blocked with 5% non-fat milk and incubated with primary antibodies.

DATA AND SOFTWARE AVAILABILITY
The accession numbers for raw sequencing data reported in this study are
GEO: GSE77661 (tissue RNA-seq), GEO: GSE109528 (cell RNA-seq), and
GEO: GSE109575 (ChIP-seq).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and three tables and can be found with this article online at
https://doi.org/10.1016/j.celrep.2018.02.002.
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